---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-008448"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:51:56.501883+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx Q1 net loss widens to $0.70 per share; Phase 3 XLRP trial actively dosing

## Summary
- Net loss of $31.0M ($0.70 per share) vs $23.6M ($0.54) in Q1 2021; R&D spend rose to $23.1M.
- Cash and equivalents of $114M plus $13.1M Janssen receivable; runway into Q4 2023.
- Phase 3 Lumeos trial of botaretigene sparoparvovec for XLRP actively dosing patients; BLA submission targeted in 2024.
- Phase 1 AQUAx trial for radiation-induced xerostomia completed all cohorts; Phase 2 planned by year-end 2022.
- IND for AAV-GAD in Parkinson's filed May 2022; riboswitch platform advancing to first-in-human studies by end of 2022.

## SEC filing metadata
- accession: 0001558370-22-008448
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000155837022008448/0001558370-22-008448-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000155837022008448/mgtx-20220512x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-008448
- JSON: https://secwatch.observer/filing/0001558370-22-008448.json
- Plain text: https://secwatch.observer/filing/0001558370-22-008448.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.